Bolt Biotherapeutics (BOLT) SEC Filings: History & Chart

Bolt Biotherapeutics, Inc.(BOLT)

Biotechnology · Redwood City, CA

$3.50+0.05 (+1.42%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.

Redwood City, CA

23 employees

www.boltbio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: William Quinn

View full financials

Form	Filing Date	Accepted	Document
4	Sep 21, 2026	Sep 21, 2026	View filing
4	Sep 21, 2026	Sep 21, 2026	View filing
4	Sep 21, 2026	Sep 21, 2026	View filing
SC 13G	Aug 13, 2026	Aug 13, 2026	View filing
10-Q	Aug 11, 2026	Aug 11, 2026	View filing
8-K	Aug 11, 2026	Aug 11, 2026	View filing
4	Jun 11, 2026	Jun 11, 2026	View filing
4	Jun 11, 2026	Jun 11, 2026	View filing
4	Jun 11, 2026	Jun 11, 2026	View filing
4	Jun 11, 2026	Jun 11, 2026	View filing
4	Jun 11, 2026	Jun 11, 2026	View filing
8-K	Jun 11, 2026	Jun 11, 2026	View filing
10-Q	May 12, 2026	May 12, 2026	View filing
8-K	May 12, 2026	May 12, 2026	View filing
ARS	Apr 28, 2026	Apr 28, 2026	View filing
DEFA14A	Apr 28, 2026	Apr 28, 2026	View filing
DEF 14A	Apr 28, 2026	Apr 28, 2026	View filing
S-8	Mar 12, 2026	Mar 12, 2026	View filing
10-K	Mar 12, 2026	Mar 12, 2026	View filing
8-K	Mar 12, 2026	Mar 12, 2026	View filing
SC 13D/A	Feb 26, 2026	Feb 26, 2026	View filing
SC 13D/A	Feb 17, 2026	Feb 17, 2026	View filing
SC 13G/A	Feb 13, 2026	Feb 13, 2026	View filing
4	Feb 4, 2026	Feb 4, 2026	View filing
4	Feb 4, 2026	Feb 4, 2026	View filing
4	Feb 4, 2026	Feb 4, 2026	View filing
4	Dec 16, 2025	Dec 16, 2025	View filing
4	Dec 16, 2025	Dec 16, 2025	View filing
4	Dec 16, 2025	Dec 16, 2025	View filing
4	Dec 16, 2025	Dec 16, 2025	View filing

SEC Filings

Recent Filings